Shoulder1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 Shoulder News
Feature Story
Shoulder Technology
Real Life Recoveries
 Education Center
Conditions
Procedures
 Shoulder  Hero™
Dr. Evan Flatow:
Innovating Shoulder Surgery
About Heroes
 Join the Discussion in  Our Forums
 Community
Shoulder1 Forums
Patient Stories
Shoulder Journals
 Reference
Ask an Expert
FAQ's
Locate a Doctor
Reference Library
Anatomy
Video Library
 Bookmark Us
 
advertisement
Search the Body1 Network
April 19, 2021  
SHOULDER NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • injection

    New Medication Could Extend Life of Arthritic Joints


    September 27, 2011

    Source: University of Rochester Medical Center

    A medication already approved to build bone mass in patients with osteoporosis also builds cartilage around joints and could potentially be repurposed to treat millions of people suffering from arthritis, according to orthopaedic researchers at the University of Rochester Medical Center.

    The study authors hope their laboratory findings, published in the current issue of Science Translational Medicine, will set the stage for the first human clinical trials to test human parathyroid hormone (brand name: Forteo) in this growing patient population.

    Since 2005, arthritis has been ranked as the leading cause of disability in the United States by the Centers for Disease Control and Prevention. And by 2030 an estimated 67 million people, or 25 percent of the adult population in this country will have osteoarthritis (OA), a painful, degenerative joint disease that often begins with an injury and results in the progressive loss of cartilage. Current treatments for OA do not help improve the cartilage in the diseased joint, they only make the pain more bearable. Examples include oral anti-inflammatory agents (such as Advil or Naproxen), narcotics, or steroid injections into the affected joint. Surgical replacement of the joint and cartilage is usually required, although this major intervention often carries its own set of complications.

     “We believe that a potential alternative to this cycle of pain and reduced quality of life has gone unnoticed for the past decade,” said study co-author Michael J. Zuscik, Ph.D., associate professor, Department of Orthopedics & Rehabilitation, Center for Musculoskeletal Research at URMC. “Given that Forteo is already FDA approved, our experimental findings make a compelling case for further clinical study of this drug in the context of arthritis.”

    The Food and Drug Administration approved Forteo a decade ago as a bone-building therapy for osteoporosis patients with severe bone loss. Although Zuscik and co-author Randy N. Rosier, M.D., Ph.D., professor of Orthopaedics & Rehabilitation, lead a laboratory that investigates osteoarthritis, through collaborative clinical work their group made an interesting observation: Occasionally, when a patient suffered from both disorders – osteoporosis and osteoarthritis – the symptoms of arthritis would improve after taking Forteo for osteoporosis.

    This observation led the OA researchers to question whether the drug would have an impact on the molecular pathways that govern chondrocytes, the cells responsible for maintaining cartilage, and the changes that take place during joint degeneration. The team used a mouse model for post-traumatic knee osteoarthritis and demonstrated in several laboratory experiments that when Forteo was given daily for one month, the injured cartilage became as much as 32 percent thicker, cell production was enhanced, and genes and molecules associated with the degeneration of cartilage were suppressed.

    The study was designed to mimic a common clinical situation in which injury to the meniscus and collateral ligaments result in the development of osteoarthritis later in life. Since the hallmark problem in osteoarthritis is the progressive and irreversible loss of cartilage, Zuscik said, the ability of parathyroid hormone to add new cartilage while blocking its degradation makes it a viable therapy.

    In addition to the laboratory research, Zuscik and Rosier reviewed OA patient information from government databases. Of 4,000 people diagnosed with knee arthritis, they found 14 who were also taking Forteo for osteoporosis. This small group of people reported less arthritis pain and a higher ability to function than a matched population of patients who were not taking Forteo.

    Although this data involved a very small number of people and is therefore not conclusive, Rosier said, it does confirm observations made by him and other URMC orthopaedic specialists.

    Future studies are still needed to address several important questions. There is some concern, for instance, about the safety of Forteo, which is made by Eli Lilly and Company and carries a black-box warning because it has been found to cause an increased risk of the bone cancer osteosarcoma, in rats. Due to this potential long-term risk in humans, Forteo is prescribed for short-term use up to two years. Thus, researchers will need to determine how long the protective/regenerative effect on cartilage persists after treatment is stopped.

    Discuss in the Shoulder1 forums

    Photo: Expert Infantry

    Last updated: 27-Sep-11

       
    Interact on Shoulder1

    Discuss this topic with others.
     
    Feature Archives

    Surgery A Treatment Option For Young Patients With Shoulder Injuries

    Recommendations For Tablet Computer Use To Avoid Shoulder Pain

    3-D Motion Detection System Could Prevent Shoulder Injuries In Baseball Pitchers

    New IDSA Guidelines Aim To Reduce Death, Disability And Cost Of Prosthetic Joint Infections

    Biceps Tenodesis Hastens Recovery From Shoulder Injuries

    Previous 5 Features ...

    Next 5 Features ...

    More Features ...
       
     
    Related Multimedia

    Interview with Dr. Patel: Roles for arthroscopic surgery in osteoarthritis/hip resurfacing

    Interview with Dr. Patel: The Reasons for Back Pain and Diagnostic Methods

    Interview with Dr. Prodromos: High Tibial Osteotomy 1

    More Features ...
     
    Related Content
    Osteoarthritis

    Degenerative Disk Disease

    Diet, Exercise May Ward Off Arthritis

    Summertime Solutions for Osteoarthritis

    Less Effective Treatments Preferred by Elderly Osteoarthritis Sufferers

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    © 2021 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.